{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/AKTS/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T05:21:38.696Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9916,"canonical_name":"Aktis Oncology, Inc.","cik":"0002035832","uei":null,"lei":null,"duns":null,"ticker":"AKTS"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":34,"clinical":2},"count":36,"timeline":[{"ts":"2026-09-24","kind":"sec.filing","form_type":"4","title":"4 — Aktis Oncology, Inc. — 2026-09-24","url_slug":"/sec/cik-0002035832/4/0001193125-26-401014","accession_number":"0001193125-26-401014","importance":30},{"ts":"2026-09-23","kind":"sec.filing","form_type":"144","title":"144 — Aktis Oncology, Inc. — 2026-09-23","url_slug":"/sec/cik-0002035832/144/0001950047-26-009770","accession_number":"0001950047-26-009770","importance":30},{"ts":"2026-09-15","kind":"clinical.trial","reporter":"Aktis Oncology, Inc.","title":"A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07581184","excerpt":"[\"Castration Resistant Metastatic Prostate Cancer\",\"Prostate Cancer\",\"mCRPC (Metastatic Castration-resistant Prostate Cancer)\",\"mCRPC\",\"B7H3\"]","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Aktis Oncology, Inc. — 2026-08-13","url_slug":"/sec/cik-0002035832/10-q/0001193125-26-349144","accession_number":"0001193125-26-349144","importance":45},{"ts":"2026-08-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Aktis Oncology, Inc. — 2026-08-13","url_slug":"/sec/cik-0002035832/8-k/0001193125-26-349133","accession_number":"0001193125-26-349133","importance":35},{"ts":"2026-07-21","kind":"sec.filing","form_type":"4","title":"4 — Aktis Oncology, Inc. — 2026-07-21","url_slug":"/sec/cik-0002035832/4/0001193125-26-310991","accession_number":"0001193125-26-310991","importance":30},{"ts":"2026-07-20","kind":"sec.form144","reporter":"KEN HERRMANN","title":"Director","shares":4856,"usd_value":119275,"security_title":"Common","approx_sale_date":"2026-07-20","accession_number":"0001950047-26-007234","importance":40.023854906},{"ts":"2026-07-20","kind":"sec.insider.s","reporter":"Herrmann Ken","title":null,"shares":3506,"price_per_share":24.5622,"usd_value":86115,"security_title":"Common Stock","importance":35.0861150732},{"ts":"2026-07-20","kind":"sec.insider.s","reporter":"Herrmann Ken","title":null,"shares":1350,"price_per_share":24.5622,"usd_value":33159,"security_title":"Common Stock","importance":35.03315897},{"ts":"2026-07-20","kind":"sec.filing","form_type":"144","title":"144 — Aktis Oncology, Inc. — 2026-07-20","url_slug":"/sec/cik-0002035832/144/0001950047-26-007234","accession_number":"0001950047-26-007234","importance":30},{"ts":"2026-07-20","kind":"sec.filing","form_type":"4","title":"4 — Aktis Oncology, Inc. — 2026-07-20","url_slug":"/sec/cik-0002035832/4/0001193125-26-309115","accession_number":"0001193125-26-309115","importance":30},{"ts":"2026-07-20","kind":"sec.insider.3506","reporter":"Herrmann Ken","title":null,"shares":3506,"price_per_share":24.5622,"usd_value":86115,"security_title":"Common Stock","importance":15.0861150732},{"ts":"2026-07-20","kind":"sec.insider.1350","reporter":"Herrmann Ken","title":null,"shares":1350,"price_per_share":24.5622,"usd_value":33159,"security_title":"Common Stock","importance":15.03315897},{"ts":"2026-07-20","kind":"sec.insider.1350","reporter":"Herrmann Ken","title":null,"shares":1350,"price_per_share":1.91,"usd_value":2579,"security_title":"Common Stock","importance":15.0025785},{"ts":"2026-07-20","kind":"sec.insider.m","reporter":"Herrmann Ken","title":null,"shares":1350,"price_per_share":1.91,"usd_value":2579,"security_title":"Common Stock","importance":15.0025785},{"ts":"2026-07-20","kind":"sec.insider.3506","reporter":"Herrmann Ken","title":null,"shares":3506,"price_per_share":0.08,"usd_value":280,"security_title":"Common Stock","importance":15.00028048},{"ts":"2026-07-20","kind":"sec.insider.m","reporter":"Herrmann Ken","title":null,"shares":3506,"price_per_share":0.08,"usd_value":280,"security_title":"Common Stock","importance":15.00028048},{"ts":"2026-07-17","kind":"sec.form144","reporter":"KEN HERRMANN","title":"Director","shares":3065,"usd_value":77259,"security_title":"Common","approx_sale_date":"2026-07-17","accession_number":"0001950047-26-007199","importance":40.015451708},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Herrmann Ken","title":null,"shares":3065,"price_per_share":25.2067,"usd_value":77259,"security_title":"Common Stock","importance":35.0772585355},{"ts":"2026-07-17","kind":"sec.filing","form_type":"144","title":"144 — Aktis Oncology, Inc. — 2026-07-17","url_slug":"/sec/cik-0002035832/144/0001950047-26-007199","accession_number":"0001950047-26-007199","importance":30},{"ts":"2026-07-17","kind":"sec.insider.m","reporter":"Herrmann Ken","title":null,"shares":3065,"price_per_share":0.08,"usd_value":245,"security_title":"Common Stock","importance":15.0002452},{"ts":"2026-07-10","kind":"sec.filing","form_type":"4","title":"4 — Aktis Oncology, Inc. — 2026-07-10","url_slug":"/sec/cik-0002035832/4/0001193125-26-300162","accession_number":"0001193125-26-300162","importance":30},{"ts":"2026-07-10","kind":"sec.filing","form_type":"4","title":"4 — Aktis Oncology, Inc. — 2026-07-10","url_slug":"/sec/cik-0002035832/4/0001193125-26-300163","accession_number":"0001193125-26-300163","importance":30},{"ts":"2026-07-08","kind":"sec.form144","reporter":"AKOS CZIBERE","title":"Officer","shares":50000,"usd_value":1388700,"security_title":"Common","approx_sale_date":"2026-07-08","accession_number":"0001950047-26-006961","importance":40.27774},{"ts":"2026-07-08","kind":"sec.form144","reporter":"SHULAMIT RON-BIGGER","title":"Officer","shares":50000,"usd_value":1387560,"security_title":"Common","approx_sale_date":"2026-07-08","accession_number":"0001950047-26-006960","importance":40.277512},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Czibere Akos","title":"Chief Medical Officer","shares":30829,"price_per_share":27.9521,"usd_value":861735,"security_title":"Common Stock","importance":35.8617352909},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Ron-Bigger Shulamit","title":"Chief Operating Officer","shares":30000,"price_per_share":27.9379,"usd_value":838137,"security_title":"Common Stock","importance":35.838137},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Ron-Bigger Shulamit","title":"Chief Operating Officer","shares":15800,"price_per_share":27.1317,"usd_value":428681,"security_title":"Common Stock","importance":35.42868086},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Czibere Akos","title":"Chief Medical Officer","shares":14800,"price_per_share":27.1273,"usd_value":401484,"security_title":"Common Stock","importance":35.40148404},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Czibere Akos","title":"Chief Medical Officer","shares":4371,"price_per_share":28.7078,"usd_value":125482,"security_title":"Common Stock","importance":35.1254817938},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Ron-Bigger Shulamit","title":"Chief Operating Officer","shares":4200,"price_per_share":28.7476,"usd_value":120740,"security_title":"Common Stock","importance":35.12073992},{"ts":"2026-07-08","kind":"sec.filing","form_type":"144","title":"144 — Ron-Bigger Shulamit — 2026-07-08","url_slug":"/sec/cik-0002049407/144/0001950047-26-006960","accession_number":"0001950047-26-006960","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"144","title":"144 — Aktis Oncology, Inc. — 2026-07-08","url_slug":"/sec/cik-0002035832/144/0001950047-26-006961","accession_number":"0001950047-26-006961","importance":30},{"ts":"2026-07-08","kind":"sec.insider.m","reporter":"Czibere Akos","title":"Chief Medical Officer","shares":50000,"price_per_share":4.95,"usd_value":247500,"security_title":"Common Stock","importance":15.2475},{"ts":"2026-07-08","kind":"sec.insider.m","reporter":"Ron-Bigger Shulamit","title":"Chief Operating Officer","shares":50000,"price_per_share":3.66,"usd_value":183000,"security_title":"Common Stock","importance":15.183},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Aktis Oncology, Inc.","title":"A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07020117","excerpt":"[\"Urothelial Carcinoma Bladder\",\"Triple Negative Breast Cancer (TNBC)\",\"Hormone Receptor Positive Breast Adenocarcinoma\",\"Non Small Cell Lung Cancer\",\"Cervical Adenocarcinoma\",\"Colorectal Adenocarcinoma\",\"Head and Neck Cancer\"]","importance":30}]}